ABS CATA-001 / Ab Studio - LARVOL DELTA

ABS CATA-001: A NOVEL CD38/AL BISPECIFIC FOR TREATING MULTIPLE MYELOMA (EHA 2026) - "Results We selected a CD38 binding arm with a unique epitope that does not compete with Daratumumab...LCMM patient serum treated with ABS CATA-001 showed better reduction of serum light chain aggregates in all five LCMM patient donors when compared to Birtamimab. Computer-aided manufacturability optimization of ABS CATA-001 validated on bench, demonstrated high purity based on SEC-HPLC data and low aggregation potential based on DLS data. Summary/Conclusion These findings demonstrate that ABS CATA-001 may serve as a next generation therapy for patients with LCMM"

Bispecific • Amyloidosis • Hematological Malignancies • Multiple Myeloma • SAA1